Calmare Therapeutics Inc

Calmare Therapeutics — Competitive Technologies — Investor Presentation (December 2013)

19 slides from Calmare Therapeutics's investor presentation, Dec 10, 2013

  1. Slide 1: Competitive Technologies, Inc. © 2013

    ‘Competitive Technologies, Inc. © 2013

  2. Slide 2: Safe Harbor Disclosure

    SEM OSes Safe Harbor Disclosure THIS PRESENTATION CONTAINS “FORWARD-LOOKING STATEMENTS” WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH FORWARD-LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN, RISKS, UNCERTAINTIES AND OTHER FACTORS WHICH MAY CAUSE THE ACTUAL RESULTS, PE

  3. Slide 3: Our Company

    somperrrve, Our Company Competitive Technologies Incorporated (CTI) is a biotechnology company that develops and commercializes innovative medical products and technologies with a concentration in pain management. * Established in 1968 and headquartered in Fairfield, CT. * Publicly traded on the OTC

  4. Slide 4: Quote on lack of effective chronic pain treatments

    Sommers "We do not yet have medications or other treatments that can effectively alleviate chronic pain with speed or efficiency in the majority of patients. Doctors treat patients with a trial-and-error approach, initially prescribing drugs with fewer side effects, reflecting the lack of effective

  5. Slide 5: What's the market opportunity?

    What's the market opportunity? $28.6 billion: Global pain management therapeutic market (CAGR of 5.3% between 2002 and 2010) 116 million: Amount of U.S. adults that experience chronic pain daily 15 million: Amount U.S. adults that suffer from neuropathic pain* CTI is targeting 5% of that 116 million

  6. Slide 6: But are prescription drugs the answer?

    A < 4, But are prescription drugs the answeré Painkiller nation: prescription sales boom across U.S. from 2000 to 2010 Prescription painkiller overdoses killed nearly over 6,000 people in the US in 2010. cTTc jristep]

  7. Slide 7: And then there's patient cost ...

    SEM OSes and then there’s patient cost ... Stimulatory Implant Medication Monthly Cost Surge! Total Cost Lyrica $180 MS Contin $135 Spinal Cord Stimulator $48,000 Oxycodone $135 Failed Back Surgery $106,000 $450 Total Monthly Annual Cost CALMARE $2,000 10 TREATMENTS $2,000

  8. Slide 8: So what's the answer?

  9. Slide 9: Calmare® Pain Device

    Calmare® Pain Device Our proprietary, patented, non-invasive medical device developed to treat high intensity oncologic and neuropathic pain without the harmful side effects and narcotic painkillers. + Immediate to prolonged pain relief after 10 to 15 treatments 1 + 510(k) cleared for sales in the U

  10. Slide 10: How does the Calmare® technology work?

    a q SENOS es How does the Calmare® technology work? 1. Certified practitioners place surface electrodes on the patient’s skin close to the pain source in order to access their C-fiber 2. Our patented multi-processor sends an algorithmically- scrambled pain message to the brain along the patient’s C-

  11. Slide 11: Indications for Calmare® use

    Indications for Calmare® use = Chemotherapy-Induced Peripheral Neuropathy (CIPN) = Intractable Cancer Pain = Failed Back Surgery Syndrome = Chronic Post-Herpetic Neuralgia (PHN) = Sciatic and Lumbar Pain = Low Back Pain (LBP) = Post-Surgical Pain = Brachial Plexus Pain = Neuropathic Pain cTTCc otc O

  12. Slide 12: So how do we fare in the clinic?

    4 So how do we fare in the clinic? Scrambler Treatment Results - 33 Cancer Patients + 33 Terminal cancer patients suffering from severe drug resistant and were treated with Calmare. Chart shows pain reduction after each treatment during 10 sessions. The pain was reduced to zero. Marineo G et al Inte

  13. Slide 13: What do the independent clinicians say?

    Sommers What do the independent clinicians say? * Mayo Clinic —Dr. Charles Loprinzi -Scrambler Therapy in Treating Chronic Pain in Patients with Rash from Varicella Zoster Virus Infection. * Mayo Clinic —Dr. Charles Loprinzi —Scrambler Therapy in Treating Pain and Peripheral Neuropathy Previously Tr

  14. Slide 14: The simple math...

    SEM OSes The simple math... Each patient: 10 treatments over 2 weeks Each Calmare device: Service 6 patients / 2 weeks = 156 patients per year 5% summary: 5.8 million patients /156 patients = 37, 000 Devices 37,000 devices @ $80,000 ===> — $2,960,000,000 Market 37,000 devices @ $40,000 7) $1,480,000

  15. Slide 15: So, how are we gonna get there?

    < Sommers ¥ So, how are we gonna get there? Conduct a sponsored, multi-center, randomized controlled pivotal trial seeking U.S. FDA approval for Calmare Drive baseline revenues through a military sales initiative seeking a “Blanket Purchase Agreement” BREAK EVEN Implement 3 tiered, paid certificatio

  16. Slide 16: What about funding?

    SEM OSes What about funding? 1. CTlis seeking a total investment of $5.0 million in two tranches: o $1.5 million in Tranche One o $3.5 million in Tranche Two - Use of Funds: - Clinical trial costs (pivotal) - Personnel: CMO and International Sales Executive - General operational expenses 2. Equity p

  17. Slide 17: What have we done lately?

    Sommers What have we done lately? 3 Months Reengineering Update (a/o 12/2/13) ¥ Shareholder value up 8X ($ 0.5 - $ 0.42) v Average daily volume up 10X (12,000 to 127,000) v Regained OTCQX listing compliance ¥ Reduced “Burn” by over 60% ($386,000 to $111,000) Financial Data (select) Stock Price (12/2

  18. Slide 18: Our Board of Directors

    Our Board of Directors Peter Brennan, Chairman - As Chairman and the largest shareholder of the company Mr, Brennan brings financial and governance leadership to the company. He spent the last 30 years working in the investment management business and is the founder of Damel Investments LLC which in

  19. Slide 19: THANK YOU!

    THANK YOU! Conrad Mir CEO Direct www.competitivetech.net

Competitive Technologies — Investor Presentation (December 2013) on 6ix